What Evidence Has Been Published for Neuronox in Essential Blepharospasm?

A prospective, randomized, double-blind, multicenter Phase III clinical trial compared Meditoxin with Botox in patients with bilateral essential blepharospasm. [1]

The publication explicitly identifies Meditoxin as another name for Neuronox.

The study included:

60 patients in the intention-to-treat population

and

52 patients in the per-protocol population.

The primary efficacy outcome was improvement in severity of spasm at four weeks after injection.

Improvement was reported in:

90.3% of the Meditoxin group

versus

86.2% of the Botox group.

The prespecified non-inferiority criterion was met in both ITT and PP analyses. [1]

What Is Essential Blepharospasm?

Essential blepharospasm is characterized by involuntary contractions of the muscles around the eyes.

These contractions can interfere with normal eyelid opening and visual function and may substantially affect daily activities.

Botulinum toxin type A has been used clinically to reduce excessive muscle contraction in this condition.

The Neuronox/Meditoxin trial specifically evaluated whether the product could provide clinical efficacy that was non-inferior to an active comparator in patients with essential blepharospasm. [1]

Who Was Included in the Study?

Participants were adults aged 18–75 years with a confirmed diagnosis of bilateral essential blepharospasm. [1]

Patients were recruited from two botulinum toxin clinics in Seoul.

Important exclusion criteria included recent BoNT-A treatment, certain muscle disorders, recent use of selected muscle-relaxing medications, pregnancy or lactation, and previous hypersensitivity to BoNT-A.

The study therefore evaluated a defined clinical population rather than all patients who may present with involuntary eyelid movements.

How Was the Trial Designed?

The study was:

• prospective;

• randomized;

• double-blind;

• multicenter;

• Phase III; and

• active-comparator controlled. [1]

A computer-generated randomization schedule assigned patients to Meditoxin or Botox.

A total of 31 patients were randomized to Meditoxin and 29 to Botox, forming the 60-patient ITT population.

After protocol exclusions, 26 patients in each group remained in the PP population. [1]

The double-blind design was maintained until the results were analyzed.

How Was Treatment Administered?

Under the study protocol, both products were reconstituted to a final concentration of 5 U/0.1 mL. [1]

The dose per injection site generally ranged from 2.5 to 5 U. For patients receiving BoNT-A for the first time, the dose per injection was 1.25 to 2.5 U.

The total dose was limited to 60 U per patient.

Injection sites included defined areas of the upper and lower eyelids and above the eyebrow.

These dosing details describe the protocol used in this particular trial and should not be interpreted as a universal dosing recommendation.

What Was the Primary Endpoint?

The primary efficacy outcome was improvement in severity of spasm, or SS, at four weeks after injection. [1]

Spasm severity was graded on a clinical scale from 0 to 4.

A primary responder was defined according to improvement in the study's severity-of-spasm assessment.

This endpoint directly evaluated the clinical problem the treatment was intended to address: excessive involuntary eyelid-muscle contraction.

What Were the Main Efficacy Results?

At four weeks, improvement in severity of spasm was reported in:

Meditoxin: 90.3%

Botox: 86.2%. [1]

The mean SS score in the ITT population also improved significantly from baseline in both groups.

In the Meditoxin group, mean SS changed from:

3.5 ± 0.6 before treatment

to

1.5 ± 0.9 at four weeks.

In the Botox group, it changed from:

3.4 ± 0.7

to

1.3 ± 1.1. [1]

Both within-group improvements were statistically significant.

Did Meditoxin Meet the Non-Inferiority Criterion?

Yes.

The study defined a non-inferiority margin of −15%. [1]

The reported lower limits of the 95% confidence interval were:

−1.76% in the ITT analysis

and

−1.64% in the PP analysis.

Both remained above the prespecified −15% threshold.

The study therefore concluded that Meditoxin was non-inferior to Botox for the primary efficacy outcome in both ITT and PP analyses. [1]

This is the appropriate primary interpretation.

The numerical difference of 90.3% versus 86.2% should not be converted into a superiority claim.

What Did the Secondary Outcomes Show?

Secondary efficacy assessments included:

• change in severity-of-spasm score;

• eyelid closing force;

• functional visual status; and

• duration of action. [1]

The publication reported no significant between-group differences in changes in eyelid closing force or functional visual status at four weeks.

The reported duration of action was also similar between groups.

These findings provide additional context to the primary non-inferiority analysis.

However, secondary endpoints should not replace the prespecified primary endpoint when summarizing the principal trial conclusion.

Did Previous Botulinum Toxin Exposure Affect the Findings?

The investigators also explored outcomes according to previous exposure to BoNT-A.

Patients in the PP population were divided into those with five or fewer previous injections and those with more than five.

The study reported no significant between-group differences in primary or secondary efficacy outcomes within these subgroups. [1]

A multiple regression analysis also did not identify sex, age, previous injection category, past illness history, baseline SS score or total injection dose as significant influences on the primary efficacy outcome in this study.

These analyses are supportive and exploratory rather than substitutes for the primary randomized comparison.

What Did the Trial Report About Safety?

Adverse effects were reported in:

16.1% of the Meditoxin group

and

27.6% of the Botox group. [1]

The between-group difference in adverse-effect frequency was not statistically significant.

The publication reported that adverse effects were mild and temporary and that no serious adverse events occurred in either group.

Reported effects in the Meditoxin group included ptosis, foreign-body sensation and irritation. [1]

Therefore, the lower numerical adverse-event percentage should not be interpreted as proof that Meditoxin/Neuronox was safer than the comparator.

Were Botulinum Toxin Antibodies Evaluated?

Yes.

This trial also included qualitative testing for antibodies against botulinum toxin type A using a mouse diaphragm assay. [1]

All 60 patients were tested initially, and 58 underwent testing at the final visit.

No positive antibody tests were reported.

However, the authors specifically noted an important limitation: the toxin doses may not have been high enough and the follow-up may not have been long enough to observe antibody formation. [1]

The result should therefore be described as:

No positive antibody tests were detected under the conditions and follow-up of this study.

It should not be expanded into a claim that Neuronox cannot induce neutralizing antibodies.

Why Is This Study Important for Neuronox?

This study adds product-specific evidence in a therapeutic indication.

It shows that the product identified in the publication as Meditoxin/Neuronox was evaluated in a:

randomized, double-blind, multicenter Phase III comparative trial.

The study included 60 patients in the ITT analysis, assessed a clinically relevant primary endpoint at four weeks and demonstrated non-inferiority under the prespecified statistical framework. [1]

This is different from assuming that the product should perform in a certain way simply because it belongs to the BoNT-A class.

Does 90.3% Versus 86.2% Mean Neuronox Was Better?

No.

Although the numerical improvement rate was 90.3% with Meditoxin and 86.2% with Botox, the trial was designed and analyzed as a non-inferiority study, not as a superiority study. [1]

The supported conclusion is therefore:

Meditoxin/Neuronox met the prespecified non-inferiority criterion for the primary efficacy outcome.

The numerical difference alone does not establish superiority.

Does the Trial Prove a Universal 1:1 Dose Conversion?

No.

The publication studied the products under a defined protocol and used a 1:1 numerical unit relationship within that trial. [1]

The authors discussed the products in that context, but a single head-to-head trial does not establish a universal conversion rule for all BoNT-A products, indications, muscles or treatment protocols.

The evidence should remain attached to the products and clinical setting actually studied.

What Are the Main Limitations?

Several limitations are important when interpreting this trial.

The sample size was relatively modest, with 60 patients in the ITT population and 52 in the PP population.

The primary efficacy assessment was performed at four weeks.

The antibody analysis had limited ability to assess long-term immunogenicity.

The findings apply specifically to essential blepharospasm and should not be extrapolated directly to aesthetic indications.

The study also disclosed industry funding, which should remain visible when evaluating the evidence.

What Funding Information Was Disclosed?

The publication states that the study received funding support from Pacific Pharmaceuticals, Inc. and Medy-Tox and acknowledges ADM Korea for research organization and statistical consultation. [1]

The trial was registered as ClinicalTrials.gov NCT00682760.

Funding disclosure does not by itself invalidate a clinical trial, but it is relevant context when reviewing study design, conduct, statistical analysis and reporting.

Bottom Line

The randomized Phase III study provides product-specific therapeutic evidence for Neuronox/Meditoxin in essential blepharospasm.

Among 60 patients in the ITT population, improvement in severity of spasm at four weeks was reported in:

90.3% with Meditoxin

versus

86.2% with Botox.

The lower limits of the 95% confidence interval remained above the study's −15% non-inferiority threshold in both ITT and PP analyses, supporting non-inferiority for the primary efficacy outcome. [1]

No serious adverse events were reported, and no positive antibody tests were detected under the study conditions, although the authors noted limitations of dose and follow-up for evaluating antibody formation.

The evidence therefore supports a precise conclusion:

Neuronox/Meditoxin has published randomized, double-blind Phase III comparative evidence in essential blepharospasm, with the primary efficacy analysis meeting the study's prespecified non-inferiority criterion.

Reference

1. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137. PMID:19794937. PMCID:PMC2739960. ClinicalTrials.gov: NCT00682760.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.